Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies

Frontiers in Oncology

Volumn 5, Issue DEC, 2015, Pages

  Pettit, Kristen ^a   Odenike, Olatoyosi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute myeloid leukemia; Elderly; Fitness; Older; Treatment

Indexed keywords

AZACITIDINE; CD34 ANTIGEN; CYTARABINE; DECITABINE; DOT1 LIKE HISTONE H3 METHYLTRANSFERASE; GEMTUZUMAB OZOGAMICIN; HISTONE METHYLTRANSFERASE; HYDROXYUREA; QUIZARTINIB; TRAMETINIB; UNCLASSIFIED DRUG; VOLASERTIB; VOSAROXIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL DECISION MAKING; COGNITION; COMORBIDITY; EPIGENETICS; HUMAN; INTENSIVE CARE; INTRACELLULAR SIGNALING; LEUKEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL PERFORMANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; TUMOR MICROENVIRONMENT;

EID: 84954482944     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00280     Document Type: Article

References (80)

1. SEER Stat Fact Sheets. Leukemia (2007-2011). (2014). Available from: http://seer.cancer.gov/statfacts/html/leuks.html.
2. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood (2009) 113(18):4179-87. doi: 10.1182/blood-2008-07-172007.
3. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica (2012) 97(12):1916-24. doi:10.3324/haematol.2012.066100.
4. Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, et al. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland. Tumori (2009) 95(3):303-10.
5. Alibhai SM, Leach M, Minden MD, Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer (2009) 115(13):2903-11. doi:10.1002/cncr.24373.
6. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood (2005) 106(4):1154-63. doi:10.1182/blood-2005-01-0178.
7. Burnett AK. The challenge of AML in older patients. Mediterr J Hematol Infect Dis (2013) 5(1):e2013038. doi:10.4084/MJHID.2013.038.
8. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood (2001) 98(5):1312-20. doi:10.1182/blood. V98.5.1312.
9. Buchner T, Berdel WE, Wormann B, Schoch C, Haferlach T, Schnittger S, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol (2005) 56(2):247-59. doi:10.1016/j.critrevonc.2004.09.010.
10. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood (2006) 107(9):3481-5. doi:10.1182/blood-2005-09-3724.
11. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica (2004) 89(9):1082-90.
12. CALGB, Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood (2006) 108(1):63-73. doi:10.1182/blood-2005-11-4354.
13. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2009) 27(1):61-9. doi:10.1200/JCO.2007.15.4245.
14. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 28(4):596-604. doi:10.1200/JCO.2009.25.1496.
15. Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia (2014) 28(10):1953-9. doi:10.1038/leu.2014.90.
16. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol (2012) 30(36):4515-23. doi:10.1200/JCO.2012.43.4738.
17. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc (2011) 59(10):1837-46. doi:10.1111/j.1532-5415.2011.03614.x.
18. Corsonello A, Lattanzio F, Pedone C, Garasto S, Laino I, Bustacchini S, et al. Prognostic significance of the short physical performance battery in older patients discharged from acute care hospitals. Rejuvenation Res (2012) 15(1):41-8. doi:10.1089/rej.2011.1215.
19. Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer (2007) 109(7):1376-83. doi:10.1002/cncr.22537.
20. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood (2013) 121(21):4287-94. doi:10.1182/blood-2012-12-471680.
21. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol (1989) 7(9):1268-74.
22. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer (2006) 106(5):1090-8. doi:10.1002/cncr.21723.
23. Wedding U, Rohrig B, Klippstein A, Fricke HJ, Sayer HG, Hoffken K. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol (2006) 132(10):665-71. doi:10.1007/s00432-006-0115-7.
24. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol (2007) 136(4):624-7. doi:10.1111/j.1365-2141.2006.06476.x.
25. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, et al. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. Hematology (2012) 17(2):53-8. doi:10.1179/102453312X13221316477651.
26. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol (2009) 145(5):598-605. doi:10.1111/j.1365-2141.2009.07663.x.
27. Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet (2010) 376(9757):2000-8. doi:10.1016/S0140-6736(10)62105-8.
28. Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood (2010) 116(6):971-8. doi:10.1182/blood-2010-01-267302.
29. Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia (2013) 27(5):997-9. doi:10.1038/leu.2012.303.
30. Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2014) 2014(1):8-13. doi:10.1182/asheducation-2014.1.8.
31. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2010) 115(3):453-74. doi:10.1182/blood-2009-07-235358.
32. Borlenghi E, Pagani C, Basilico C, Bernardi M, Fracchiolla N, Guidotti F, et al. Validating the patient's "fitness" criteria proposed to guide treatment decision in elderly AML: a multicenter study on a population-based series of 362 patients by the network "Rete Ematologica Lombarda" (REL). ASH Annu Meet Oral Abstr (2014). Available from: http://www.bloodjournal.org/content/124/21/279.full.pdf.
33. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol (2012) 30(21):2670-7. doi:10.1200/JCO.2011.38.9429.
34. Kantarjian H, Wilson W, Ravandi F, Estey E. Decitabine in older adults with acute myeloid leukemia: why was the dream broken? J Clin Oncol (2013) 31(14):1795-6. doi:10.1200/JCO.2012.48.1465.
35. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 107(16):7473-8. doi:10.1073/pnas.1002650107.
36. Decitabine With or Without Bortezomib in Treating Older Patients With AML (2014). (2014). Available from: http://www.clinicaltrials.gov/show/NCT01420926.
37. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 20(10):2429-40. doi:10.1200/JCO.2002.04.117.
38. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2010) 28(4):562-9. doi:10.1200/JCO.2009.23.8329.
39. Dombret HS, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. Results of a Phase 3, Multicenter, Randomized, Open-Label Study of Azacitidine (Aza) vs Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Milan: European Hematology Association (2014).
40. Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. Azacitidine versus conventional care regimens in older patients with newly diagnosed acute myeloid leukemia with morphologic dysplastic changes: a subroup analysis of the AZA-AML-001 trial. ASH Annu Meet Oral Abstr (2014). Available from: https://ash.confex.com/ash/2014/webprogram/Paper71181.html.
41. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia (2012) 26(5):1106-7. doi:10.1038/leu.2011.342.
42. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma (2014) 55(8):1925-9. doi:10.3109/10428194.2013.855309.
43. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood (2014) 124(17):2705-12. doi:10.1182/blood-2014-06-582809.
44. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia (2011) 25(7):1147-52. doi:10.1038/leu.2011.71.
45. Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica (2013) 98(1):119-28. doi:10.3324/haematol.2012.066613.
46. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 19(13):3244-54.
47. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 104(7):1442-52. doi:10.1002/cncr.21326.
48. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 7(6):1490-6.
49. Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annu Meet Oral Abstr (2009). Available from: https://ash.confex.com/ash/2009/webprogram/Paper22999.html.
50. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 30(32):3924-31. doi:10.1200/JCO.2012.42.2964.
51. Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia (2013) 27(1):75-81. doi:10.1038/leu.2012.229.
52. Lowenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 115(13):2586-91. doi:10.1182/blood-2009-10-246470.
53. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood (2013) 121(24):4838-41. doi:10.1182/blood-2013-03-490482.
54. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 30(32):3921-3. doi:10.1200/JCO.2012.43.0132.
55. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2011) 29(4):369-77. doi:10.1200/JCO.2010.31.4310.
56. A Study to Evaluate PF-04449913 with Chemotherapy in Patients with AML or MDS (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT01546038.
57. Dohner H, Lubbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood (2014) 124(9):1426-33. doi:10.1182/blood-2014-03-560557.
58. Volasertib in Combination with Low-Dose Cytarabine in Patients Aged 65 Years and Above with Previously Untreated Acute Myeloid Leukemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT01721876.
59. Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Acute Myeloid Leukemia (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT01907815.
60. Levis MPA, Dombret H. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. ASH Annu Meet Oral Abstr (2012). Available from: https://ash.confex.com/ash/2012/webprogram/Paper54037.html.
61. AC220 with 5-Aza or Low Dose Cytarabine (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT01892371.
62. Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory AML (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT02014558.
63. Swords RT, Savona MR, Maris M, Erba HP, Berdeja JG, Foran JM, et al. Pevonedistat (MLN4924), an investigational, first-in-class NAE inhibitor, in combination with azacitidine in elderly patients with acute myeloid leukemia considered unfit for conventional chemotherapy: updated results from the phase 1 C15009 trial. ASH Annu Meet Poster Abstr (2014). Available from: https://ash.confex.com/ash/2014/webprogram/Paper69201.html.
64. Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients with AML Who Are 60 Years or Older (2014). (2014). Available from: https://clinicaltrials.gov/show/NCT01814826.
65. Safety and Efficacy Study of Pracinostat with Azacitidine in Elderly Patients with Newly Diagnosed AML (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT01912274.
66. Raffoux E, Cras A, Recher C, Boelle PY, de Labarthe A, Turlure P, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget (2010) 1(1):34-42. doi:10.18632/oncotarget.106.
67. Decitabine (DAC) With or Without Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (2014). ClinicalTrials.gov: US National Institutes of Health (2014). Available from: http://clinicaltrials.gov/show/NCT00414310.
68. Study of Vosaroxin and Decitabine in Older Patients with AML and High-Risk MDS (2014). (2014). Available from: https://clinicaltrials.gov/show/NCT01893320.
69. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation (2014). (2014). Available from: https://clinicaltrials.gov/show/NCT02074839.
70. Phase 1 Study of AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT01915498.
71. Dose Escalation Study of EPZ-5676 in Pediatric Patients with Leukemias Bearing a Rearrangement of the MLL Gene (2014). (2014). Available from: https://clinicaltrials.gov/show/NCT02141828.
72. SGI-110 in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) (2015). (2015). Available from: https://clinicaltrials.gov/ct2/show/NCT01261312.
73. Selinexor (KPT-330) in Older Patients with Relapsed AML (SOPRA) (2014). (2014). Available from: http://clinicaltrials.gov/show/NCT02088541.
74. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 114(1):144-7. doi:10.1182/blood-2009-03-210039.
75. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol (2013) 31(29):3681-7. doi:10.1200/JCO.2013.48.8783.
76. Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, et al. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs (2015) 33(2):371-9. doi:10.1007/s10637-014-0194-2.
77. Garcia-Manero G, Atallah E, Odenike O, Medeiros BC, Cortes J, Esquibel V, et al. Pracinostat in combination with azacitidine produces a high rate and rapid onset of disease remission in patients with previously untreated acute myeloid leukemia. ASH Annu Meet Poster Abstr (2014). Available from: https://ash.confex.com/ash/2014/webprogram/Paper69374.html.
78. Naval D, Kantarjian HM, Garcia-Manero G, Jabbour E, Pemmaraju N, Vaughan K, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients with AML and high risk MDS. ASH Annu Meet Oral Abstr (2014). Available from: https://ash.confex.com/ash/2014/webprogram/Paper75224.html.
79. Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 119(25):6025-31. doi:10.1182/blood-2012-03-413898.
80. Yoshimi A, Kurokawa M. Key roles of histone methyltransferase and demethylase in leukemogenesis. J Cell Biochem (2011) 112(2):415-24. doi:10.1002/jcb.22972.